Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free EGRX Stock Alerts

Eagle Pharmaceuticals (EGRX) Competitors

Eagle Pharmaceuticals logo
$0.37 0.00 (0.00%)
As of 07/24/2026
Compare

EGRX vs. MRKR, ATOS, PLUR, NRSN, and MDCX

Should you buy Eagle Pharmaceuticals stock or one of its competitors? MarketBeat compares Eagle Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eagle Pharmaceuticals include Marker Therapeutics (MRKR), Atossa Genetics (ATOS), Pluri (PLUR), NeuroSense Therapeutics (NRSN), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry.

How does Eagle Pharmaceuticals compare to Marker Therapeutics?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 719.67%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Eagle Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eagle Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Eagle Pharmaceuticals has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$257.55M0.02$35.64M$1.180.31
Marker TherapeuticsN/AN/A-$12.16M-$0.61N/A

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Eagle Pharmaceuticals has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Eagle Pharmaceuticals' return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eagle PharmaceuticalsN/A N/A N/A
Marker Therapeutics -343.03%-73.29%-59.70%

In the previous week, Eagle Pharmaceuticals and Eagle Pharmaceuticals both had 1 articles in the media. Marker Therapeutics' average media sentiment score of 1.89 beat Eagle Pharmaceuticals' score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Eagle Pharmaceuticals Neutral
Marker Therapeutics Very Positive

Summary

Eagle Pharmaceuticals beats Marker Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Atossa Genetics presently has a consensus target price of $20.33, indicating a potential upside of 784.06%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities analysts plainly believe Atossa Genetics is more favorable than Eagle Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Eagle Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Eagle Pharmaceuticals' return on equity of 0.00% beat Atossa Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atossa GeneticsN/A -84.91% -72.36%
Eagle Pharmaceuticals N/A N/A N/A

In the previous week, Atossa Genetics had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for Atossa Genetics and 1 mentions for Eagle Pharmaceuticals. Atossa Genetics' average media sentiment score of 0.94 beat Eagle Pharmaceuticals' score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Atossa Genetics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eagle Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Atossa Genetics has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Eagle Pharmaceuticals has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atossa GeneticsN/AN/A-$34.77M-$3.21N/A
Eagle Pharmaceuticals$257.55M0.02$35.64M$1.180.31

Summary

Eagle Pharmaceuticals beats Atossa Genetics on 8 of the 14 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Pluri?

Pluri (NASDAQ:PLUR) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Eagle Pharmaceuticals has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluri$1.08M17.80-$22.58M-$4.53N/A
Eagle Pharmaceuticals$257.55M0.02$35.64M$1.180.31

Pluri has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

16.6% of Pluri shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 43.2% of Pluri shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Pluri and Pluri both had 1 articles in the media. Pluri's average media sentiment score of 0.94 beat Eagle Pharmaceuticals' score of 0.00 indicating that Pluri is being referred to more favorably in the media.

Company Overall Sentiment
Pluri Positive
Eagle Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluri
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Eagle Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Eagle Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%.

Company Net Margins Return on Equity Return on Assets
Pluri-2,162.08% N/A -106.59%
Eagle Pharmaceuticals N/A N/A N/A

Summary

Eagle Pharmaceuticals beats Pluri on 8 of the 12 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to NeuroSense Therapeutics?

Eagle Pharmaceuticals (NASDAQ:EGRX) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Eagle Pharmaceuticals has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$257.55M0.02$35.64M$1.180.31
NeuroSense TherapeuticsN/AN/A-$11.12M-$0.54N/A

NeuroSense Therapeutics has a consensus target price of $8.50, indicating a potential upside of 1,311.73%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Eagle Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eagle Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NeuroSense Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 1 mentions for Eagle Pharmaceuticals. NeuroSense Therapeutics' average media sentiment score of 0.94 beat Eagle Pharmaceuticals' score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eagle Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
NeuroSense Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
Eagle PharmaceuticalsN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

NeuroSense Therapeutics beats Eagle Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, Medicus Pharma had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for Medicus Pharma and 1 mentions for Eagle Pharmaceuticals. Medicus Pharma's average media sentiment score of 0.47 beat Eagle Pharmaceuticals' score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Medicus Pharma Neutral
Eagle Pharmaceuticals Neutral

Medicus Pharma has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Eagle Pharmaceuticals' return on equity of 0.00% beat Medicus Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Medicus PharmaN/A -3,137.84% -311.33%
Eagle Pharmaceuticals N/A N/A N/A

Medicus Pharma currently has a consensus target price of $9.00, suggesting a potential upside of 2,332.43%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Eagle Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medicus Pharma
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Eagle Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Eagle Pharmaceuticals has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicus PharmaN/AN/A-$35.46M-$2.68N/A
Eagle Pharmaceuticals$257.55M0.02$35.64M$1.180.31

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 8.1% of Medicus Pharma shares are held by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Eagle Pharmaceuticals beats Medicus Pharma on 9 of the 14 factors compared between the two stocks.

Get Eagle Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EGRX vs. The Competition

Export
MetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.81M$975.11M$6.86B$12.25B
Dividend YieldN/A4.84%2.67%9.79%
P/E Ratio0.311.5327.1423.64
Price / Sales0.02105.75517.0189.03
Price / Cash0.4020.0650.5459.64
Price / BookN/A8.4710.286.07
Net Income$35.64M-$2.70M$3.60B$331.99M
7 Day Performance-37.82%-2.29%-1.27%-0.63%
1 Month Performance-38.33%-3.97%-0.37%-2.00%
1 Year Performance-89.97%27.39%18.30%13.62%

Eagle Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EGRX
Eagle Pharmaceuticals
N/A$0.37
flat		N/A-90.0%$4.81M$257.55M0.31100
MRKR
Marker Therapeutics
2.6358 of 5 stars		$1.28
+0.4%		$10.00
+684.3%		-18.7%$21.25M$3.55MN/A60
ATOS
Atossa Genetics
2.2367 of 5 stars		$2.45
+2.1%		$20.33
+729.9%		-82.2%$21.09MN/AN/A8
PLUR
Pluri
0.4007 of 5 stars		$1.96
+0.3%		N/A-65.2%$21.09M$1.08MN/A150
NRSN
NeuroSense Therapeutics
3.5948 of 5 stars		$0.65
-7.4%		$8.50
+1,211.7%		-70.3%$21.06MN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EGRX) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel